Perinatal synthetic lethality and hematopoietic defects in compound mafG::mafK mutant mice
AUTOR(ES)
Onodera, Ko
FONTE
Oxford University Press
RESUMO
Prior studies exploring the mechanisms controlling erythroid gene regulation implicated MARE (Maf recognition element) cis–elements as crucial to the transcriptional activity of many erythroid genes. Numerous transcription factors can elicit responses through MAREs, including not only the AP-1 family proteins, but also a growing list of factors composed of Cap-N-Collar (CNC)–small Maf heterodimers. While these factors can activate transcription from MAREs in co-transfection assays, mouse germline mutations in cnc genes tested to date have failed to reveal primary erythroid phenotypes. Here we report that after combining the mafK and mafG targeted null alleles, mutant animals display several synthetic phenotypes, including erythroid deficiencies. First, compound homozygous small maf gene mutants survive embryogenesis, but die postnatally. Secondly, compound mutant animals develop severe neurological disorders. Thirdly, they exhibit an exacerbated mafG deficiency in megakaryopoiesis, specifically in proplatelet formation, resulting in profound thrombocytopenia. Finally, the compound mutant animals develop severe anemia accompanied by abnormal erythrocyte morphology and membrane protein composition. These data provide direct evidence that the small Maf transcription factors play an important regulatory role in erythropoiesis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=305674Documentos Relacionados
- Impaired megakaryopoiesis and behavioral defects in mafG-null mutant mice
- One enhancer mediates mafK transcriptional activation in both hematopoietic and cardiac muscle cells
- Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice.
- Multiple hematopoietic defects and delayed globin switching in Ikaros null mice
- Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3